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a b s t r a c t 
Background: Understanding patient pathways can help align patient preferences and tuberculosis (TB) re- 
lated services. We investigated patient pathways, and diagnostic and treatment delays among TB patients 
in Indonesia, which has one of the highest proportions of non-notified TB cases globally. 
Methods: We conducted a study of TB patients recruited from Community Health Centers (CHCs), public 
and private hospitals, and private practitioners from 2017 to 2019 in Bandung City, regarding general 
characteristics and symptoms, and health-seeking, diagnostic and treatment pathways. 
Findings: We recruited 414 TB patients: 138 (33%) in CHCs, 210 (51%) in hospitals, 66 (20%) in private 
practitioners. Most patients (74 ·6%) first sought care at an informal or private provider and experienced a 
complex pathway visiting both public and private providers to obtain a diagnosis. The median number of 
health provider visits pre-diagnosis was 6 (IQR 4–8). From start of symptoms, it took a median 30 days 
(IQR 14–61) to present to a health provider, 62 days (IQR 35–113) to reach a TB diagnosis, and 65 days 
(IQR 37–119) to start treatment. Patient delay was longer among male, lowly-educated and uninsured 
individuals. There were longer diagnostic delays among uninsured individuals, those who initially visited 
private providers, and those with multiple visits prior to diagnosis. Longer treatment delays were found 
in those with multiple pre-diagnosis visits or diagnosed by private practitioners. 
Interpretation: Patient pathways in Indonesia are complex, involving the public and private sector, with 
multiple visits and long delays, especially to diagnosis. A widely available accurate diagnostic test for TB 
could have a dramatic effect on reducing delays, onward transmission and mortality. 
Funding: This project was funded by the Partnership for Enhanced Engagement in Research (PEER) 
grant under Prime Agreement Number AID-OAA-A-11–00,012 by National Academy of Sciences (NAS); 
the United States Agency for International Development (USAID); University of Otago, New Zealand, and 
the Indonesian Endowment Fund for Education (LPDP). 
© 2020 The Authors. Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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Evidence before this study 
Globally almost 3 million TB cases are thought to be under- 
diagnosed, or detected but not reported. Providing accurate, 
accessible and timely diagnosis and treatment, and knowing 
where those cases are, is crucial for TB control. Patient path- 
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way analysis (PPA) is an approach to identify where miss- 
ing cases occur and possible reasons for delay to diagnosis 
and treatment. Delay to diagnosis and treatment of TB can 
contribute to late presentation, more severe disease, ongoing 
transmission of M. tuberculosis , and increased out-of-pocket 
costs. 
Indonesia has a high prevalence of TB. Previous studies 
have shown the role of private health care providers in TB 
patient care seeking patient pathways. However, evidence is 
lacking to respond to variances in care-seeking patterns and 
the capacities of public and private providers for TB control. 
Added value of this study 
From our study which recruited TB patients from differ- 
ent health care settings, we were able to identify key factors 
related to delay in presentation and diagnosis of TB. In par- 
ticular the pathways involving informal, and formal private 
and public health care providers contributed to the complex- 
ity and long delays. 
Implications of all the available evidence 
Greater partnership between, and strengthening of, the 
public and private sectors for diagnosis and reporting of TB is 
essential for the control of TB in Indonesia. Patient-centered, 
easy to access TB diagnosis and treatment centres with all 
available tools in one place is essential and would have a dra- 
matic effect on TB control in Indonesia. 
1. Introduction 
The large number of undiagnosed or non-notified tuberculosis 
(TB) cases is a global public health concern. In 2018, an estimated 
three million TB cases were thought to be under-diagnosed, or de- 
tected but not reported, many of whom were in low- and middle- 
income countries (LMICs) [1] . India, Indonesia, and Nigeria are the 
top three countries contributing almost 50% of the total undiag- 
nosed or non-notified cases worldwide [1] . Finding these TB pa- 
tients, and providing accurate and accessible diagnosis and treat- 
ment according to international standards in a timely way are cru- 
cial for disease control [2] . 
Patient pathway analysis (PPA) is an approach to identify bar- 
riers to all TB patients’ access to diagnostic and treatment ser- 
vices. PPA has proved to be a valuable tool informing stakeholders 
for allocating TB diagnostic and treatment facilities from a patient 
centered-care perspective [3] . Previous PPA studies have demon- 
strated that there are substantial differences between patients’ 
care-seeking behavior and TB service availability [3] . In a recent 
study in Taiwan, Ku et.al. used longitudinal routine national health 
insurance data to generate individual TB patients’ care-seeking 
pathways and reported considerable heterogeneity and complex 
pathways leading to TB diagnosis [5] . 
Delay to diagnosis and treatment of TB can contribute to late 
presentation, more severe disease, ongoing transmission of M. tu- 
berculosis , and increased out-of-pocket costs [6 , 7] . Delay can be 
classified as patient delay or health system delay. A range of fac- 
tors have been associated with both these delays [8] . In a mod- 
eling study, delay before a patient’s presentation to a healthcare 
provider appeared to account for most of the delay in the pa- 
tient pathway to care [4] . Unemployment, low income, low ed- 
ucation level, pulmonary abnormalities, having HIV, and seeking 
initial care from an informal provider were associated with pa- 
tient delay across studies and locations [ 9 , 10 ]. Consulting multi- 
ple health care providers and seeking initial care from a private 
provider have been consistently associated with health system de- 
lay [ 11 , 12 ]. Other factors that have been found, but less consis- 
tently, include patient factors such as gender and residence type, 
and health system factors such as consultation at a public, rather 
than a private, hospital [ 8-10 , 12 ]. 
We aimed to describe patient trajectories, measure time from 
presentation to TB diagnosis and from diagnosis to treatment, 
and identify factors associated with delays, in an urban setting 
in Indonesia, which has a complicated public-private health care 
provider network and one of the highest proportions of undiag- 
nosed or non-notified TB cases globally [1] . 
2. Methods 
2.1. Study design and setting 
This cross-sectional study was conducted over a two-year pe- 
riod in Bandung, the capital of West Java province, Indonesia, a city 
with 2 ·5 million inhabitants. In 2018, the TB case notification rate 
in Bandung was 402/10 0,0 0 0/ year and the treatment success rate 
was 79% [13] . TB diagnosis and treatment are provided according 
to the National Guidelines for TB Control issued by the Ministry 
of Health. Diagnosis mostly relies on passive case finding, whereby 
patients present to a health facility when they are unwell [14] . TB 
related services in Bandung are provided through a network of 73 
Community Health Centers (CHCs), one lung clinic, one lung hos- 
pital, 16 secondary level hospitals, four prison clinics, and one ter- 
tiary level hospital. Of these services, 88% are publicly funded. In 
CHCs and hospitals, TB diagnosis is mostly through sputum smear 
examination. According to the National Tuberculosis Program (NTP) 
guideline, presumptive TB patients with negative sputum smear re- 
sult, and suggestive chest x-ray findings of TB are diagnosed as 
clinical TB [14] . Thirty of the 73 CHCs (41 ·1%) have sputum smear 
microscopy facilities. No CHC and only five out of sixteen hospitals 
used Xpert/MTB-RIF as a molecular test for TB diagnosis within the 
study period. Culture and drug-sensitivity test (DST) are only per- 
formed for rifampicin-resistant TB patients and conducted at the 
provincial reference laboratory. TB treatment can be obtained in 
either the public sector (CHCs, public hospitals) or in private hos- 
pitals that are parts of Directly Observed Treatment Short-course 
(DOTS) network. There is also a relatively large number of approx- 
imately 2435 private practitioners (PPs) in Bandung, either working 
in solo practices or in clinics with other PPs. Some of these PPs are 
engaged in the NTP for referring presumptive TB cases, diagnosing 
or providing treatment. However, little is known about the exact 
number of PPs managing TB cases. A national TB inventory study 
conducted in 2017 showed that approximately 39% of detected TB 
cases from PPs, private clinics and laboratories were not notified to 
the NTP [13] . 
2.2. Study population 
Thirty sub-districts in Bandung were randomly selected in pro- 
portion to population size. These contained 30 CHCs, seven public 
hospitals, and 10 private hospitals, from which we randomly se- 
lected 10 CHCs and purposively selected two public and three pri- 
vate hospitals according to the number of new TB cases detected, 
as well as willingness of hospital management to collaborate in the 
study. Subsequently, we conducted a survey to identify PPs in the 
CHC areas who had diagnosed and treated TB patients in the pre- 
ceding six months ( n = 282/939). Out of 282 PPs, 145 PPs were 
willing to participate in this study. Based on the 2015 TB report 
from the Bandung Municipal Health Office, a total of 2087 positive 
TB patients were notified by the 73 CHCs (average of 28 patients 
per CHC per year), and a further 3560 from DOTS linkage hospitals 
and lung clinics. From these numbers, we estimated that 37% of 
TB patients were registered in CHCs and 63% in hospitals. As infor- 
mation about the number and proportion of TB patients who visit 
PPs was limited, we assumed this to be at least 30%. We therefore 
recruited 30% of patients from CHCs, 40% from hospitals and 30% 
from PPs. Taking into account a 10% non-response rate, we aimed 
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Fig. 1. Conceptual framework on definitions of delays [ 7 , 15 ]. 
for a minimum sample size of 400 TB patients comprising 120, 160 
(80 public and 80 private), and 120 patients from CHCs, hospitals, 
and PPs, respectively. 
We interviewed adults with newly diagnosed pulmonary TB and 
receiving treatment for less than six months from each recruitment 
site. We consecutively enrolled consenting patients from 1 October 
2017 to 31 January 2019 until the sample size was met. We ex- 
cluded patients who had a previous history of TB treatment (re- 
treatment cases), extrapulmonary TB and those who were not liv- 
ing in Bandung. This study was approved by the Health Research 
Ethics Committee at Faculty of Medicine, Universitas Padjadjaran 
under number 687/UN6.C.10/PN/2017. Before study enrollment, all 
patients provided written informed consent. 
2.3. Definitions 
We adopted the definition of health care providers (HCPs) de- 
veloped by Lei, et al. [15] . Public HCPs belonged to national, 
provincial, district or municipal governments which implement the 
NTP and provide TB related-services (CHCs, lung clinics, lung hos- 
pitals, and public hospitals). Private HCPs were not owned by the 
government and provide TB or general health services for profit, 
both formal and informal, regulated or not by the government 
(solo practice, private clinics or hospitals, and informal HCPs such 
as traditional healers, unauthorised practitioners, and chemists or 
pharmacists). 
We used the conceptual framework for delays based on Sreera- 
mareddy et al. [ 12 , 16 ] as depicted in Fig. 1 . Patient delay was de- 
fined as the time from onset of TB symptoms to first visit to any 
HCP. Diagnostic delay was defined as the duration between first 
HCP consultation and TB diagnosis. Treatment delay was defined 
as time between TB diagnosis and commencement of treatment. 
Health system delay was calculated as time from the first HCP con- 
sultation to TB treatment initiation. Total delay was defined as the 
sum of patient and health system delays. 
As PPA was used to describe the alignment between patient 
care seeking and the availability of TB diagnostic and treatment 
services, we defined the capacity for TB diagnosis and treatment 
for healthcare facilities in the health system according to Surya 
et al. [17] , as shown in Table 1 . 
2.4. Procedures 
Four trained nurses interviewed patients using a struc- 
tured questionnaire adapted from the “Tool to estimate patients 
costs” [18] . The questionnaire collected information on socio- 
demographic characteristics, TB symptoms, diagnostic pathways 
from onset of symptoms until TB diagnosis and treatment, type 
and sequence of providers visited, and associated costs. The ques- 
tionnaire was pre-tested in a pilot study on 20 TB patients. Dates 
for the commencement of symptoms and health-seeking events 
were self-reported. Dates of TB diagnosis and treatment start were 
obtained from medical records. Knowledge about TB was measured 
through 15 questions adapted from Naidoo et.al. [19] . A summary 
score defined “good knowledge” as ≥80% correctly answered ques- 
tions or “poor” if ˂80%. All results were cross-checked to identify 
errors, missing data, or inconsistencies. 
2.5. Analysis 
We performed descriptive analyses to summarize the data on 
patient trajectories and presented the number and type of visits for 
presumptive cases prior to a TB diagnosis, stratified by type of re- 
cruitment site. Bivariate analysis was carried out to study the asso- 
ciation between patients’ characteristics and type of HCP at initial 
presentation. We defined patient delay as more than 30 days from 
onset of symptoms to first visit to any HCP [9] ; diagnostic delay as 
more than seven days between first HCP consultation to TB diagno- 
sis [ 9 , 12 , 20 ]; and treatment delay as more than two days between 
TB diagnosis and commencing treatment [12] to dichotomize these 
delays into acceptable or longer delay. For diagnostic delay, a sec- 
ondary analysis using a cut-off of 30 days was also estimated tak- 
ing into account time variability on diagnostic procedures taken by 
the patients [ 9 , 12 ]. We used logistic regression models to examine 
the association between possible risk factors to each delay type. 
We excluded distance to the closest CHC as a covariate in our anal- 
ysis, since the majority of patients (94%) lived within 5 km from a 
CHC. Variables were considered in the final models if they were as- 
sociated with the outcome variable ( p < 0 ·2). We assessed correla- 
tion between covariates, calculating correlation coefficients. Results 
are presented as adjusted odds ratios (aOR) with 95% confidence 
intervals (CI) and a p-value < 0.05 was considered statistically sig- 
nificant. 
2.6. Role of the funding source 
The funders had no role in study design, data collection and 
analysis, decision to publish or preparation of the manuscript. The 
corresponding author had full access to all the data in the study 
and had final responsibility for the decision to submit for publica- 
tion. 
3. Results 
3.1. Socio-demographic and clinical disease characterisistics 
From 591 TB patients assessed, 131 (22 ·2%) did not meet the 
eligibility criteria, mostly due to them having extrapulmonary TB 
or living outside of Bandung city. Thirty (5 ·1%) refused to partic- 
ipate, and 16 (2 ·7%) were unable to be interviewed, leaving 414 
available for analysis (CHC n = 138; public hospital n = 106; pri- 
vate hospital n = 104; PP n = 66). Of these 414 patients, 57 ·5% 
were males, the median age was 35 years, 49 ·5% were high-school 
graduates, and 60 ·9% were employed at the time of interview. Al- 
most all patients lived within 5 km of their closest CHC (93 ·7%), 
and 28 ·5% lacked private or government health insurance ( Table 2 ). 
Most patients (88 ·6%) presented with a cough, 51 ·2% were diag- 
nosed by smear microscopy (no culture or Xpert was done) and 
the remaining were diagnosed by clinical symptoms and chest X- 
ray ( Table 2 ). One third (29 ·2%) had prior contact history with a TB 
patient, 67 ·6% took antibiotics before being diagnosed with TB, and 
43 ·5% smoked cigarettes within the past year. Based on the inter- 
view [19] , half of the patients (51 ·2%) had good knowledge about 
TB. We found only weak correlations between any of the variables 
and type of HCP at initial presentation (Appendix 2). 
3.2. Patient pathways from seeking care to diagnosis and treatment 
Overall, three quarters (76 ·8%) of patients initially visited an 
informal or private provider and a minority first visited a CHC 
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Table 1 
TB diagnosis and treatment capacity in Indonesia according to healthcare setting. 
Level Availability of TB diagnostic and treatment Example 
L0 Non-public services for basic triage, health information, and basic care, but without laboratory 
testing or TB treatment available. 
Pharmacy, drug sellers, drug stores, community-based 
organizations (with health cadres) 
L1a Government-owned facilities that provide primary health care, generally on an outpatient basis. 
Sputum smear microscopy and TB treatment may be available. 
Community Health centre (CHC) 
L1b Private facilities that provide primary health care, generally on an outpatient basis. Sputum smear 
microscopy (and other TB diagnostics) are mostly absent, but TB treatment may be available. 
Private practitioners, private clinics 
L2a Government-owned secondary level health facilities for outpatient and inpatient care, generally 
with more diagnostic services (sputum smear microscopy, x-ray, and Xpert MTB/RIF) as well as TB 
treatment. 
Public hospitals 
L2b Private facilities that provide secondary level health outpatient and inpatient care, generally with 
more diagnostic services (sputum smear microscopy, x-ray, and Xpert MTB/RIF) as well as TB 
treatment. 
Private hospitals 
L3 Specialized health care facilities with large inpatient capacity, specialized doctors and more 
sophisticated diagnostic capabilities including sputum culture with drug-susceptibility test, and 
treatment services for drug-sensitive or drug-resistant TB. 
Tertiary care hospitals 
Fig. 2. Pathways undertaken by tuberculosis patients for diagnosis and treatment according to site of recruitment ( N = 401). TB = tuberculosis. 13 people did not present 
with symptoms and were therefore excluded from this pathway analysis. L0 = informal providers (pharmacy, drug sellers, drug store, etc.); L1a = Community Health Center; 
L1b = private practitioner or private clinic; L2a = public hospital; L2b = private hospital. 
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Table 2 
Patient characteristics that contribute to delays according to the site of recruitment ( N = 414). 
Characteristic Community Health 
Center 
n = 138 (33 ·3%) 
Public hospital 
n = 106 (25 ·6%) 
Private hospital 
n = 104 (25 ·1%) 
Private Practitioner 
n = 66 (15 ·9%) 
p-value 
Age, median (IQR) 36 ·2 (27–49) 31 ·3 (23–46) 39 ·7 (24–52) 31 ·8 (24–47) 0 ·08 
Male 80 (58 ·0) 61 (57 ·5) 61 (58 ·7) 36 (54 ·5) 0 ·96 
Education 
Primary school or less 32 (23 ·2) 20 (18 ·9) 23 (22 ·1) 17 (25 ·8) 0 ·27 
Secondary school 27 (19 ·6) 12 (11 ·3) 22 (21 ·2) 9 (13 ·6) 
Senior high school 66 (47 ·8) 61 (57 ·5) 50 (48 ·1) 28 (42 ·4) 
University or higher education 13 (9 ·4) 13 (12 ·3) 9 (8 ·6) 12 (18 ·2) 
Employment status 
Employed 87 (63 ·0) 64 (60 ·4) 58 (55 ·8) 43 (65 ·2) 0 ·88 
Unemployed 14 (10 ·1) 13 (12 ·3) 15 (14 ·4) 8 (12 ·1) 
Other (student/housewife/retired) 37 (26 ·8) 29 (27 ·4) 31 (29 ·8) 15 (22 ·7) 
Household income/month, USD a 
≤230 80 (58 ·0) 38 (35 ·8) 48 (46 ·2) 16 (24 ·2) < 0 ·001 
> 230 48 (34 ·8) 51 (48 ·1) 44 (42 ·3) 43 (65 ·2) 
Refused to answer/ don’t know 10 (7 ·2) 17 (16 ·1) 12 (11 ·5) 7 (10 ·6) 
Marital status 
Married 87 (63 ·0) 57 (53 ·8) 66 (63 ·5) 35 (53 ·0) 0 ·27 
Single/divorced/widowed 51 (37 ·0) 49 (46 ·2) 38 (36 ·5) 31 (47 ·0) 
Insurance 74 (53 ·6) 84 (79 ·2) 94 (90 ·4) 44 (66 ·7) < 0 ·001 
Distance to closest CHC 
≤ 5 km 132 (95 ·7) 92 (86 ·8) 101 (97 ·1) 63 (95 ·5) 0 ·01 
> 5 km 6 (4 ·3) 14 (13 ·2) 3 (2 ·9) 3 (4 ·5) 
Level of TB knowledge 
Poor 56 (40 ·6) 41 (38 ·7) 62 (59 ·6) 43 (65 ·2) < 0 ·001 
Good 82 (59 ·4) 65 (61 ·3) 42 (40 ·4) 23 (34 ·8) 
History of contact with a TB patient 56 (40 ·6) 29 (27 ·4) 20 (19 ·2) 16 (13 ·2) 0 ·002 
Smoking within the past year 69 (50 ·0) 38 (35 ·8) 49 (47 ·1) 24 (36 ·4) 0 ·08 
Comorbidities b 
HIV 1 (0 ·7) 2 (1 ·9) 1 (1 ·0) 0 (0 ·0) 0 ·64 
Diabetes 10 (7 ·2) 7 (6 ·6) 11 (10 ·6) 6 (9 ·1) 0 ·71 
Cardiovascular disease ∗ 6 (4 ·3) 14 (13 ·2) 21 (20 ·2) 3 (4 ·5) 0 ·02 
TB symptoms c 
Cough 131 (94 ·9) 97 (91 ·5) 80 (76 ·9) 59 (89 ·4) < 0 ·001 
Hemoptysis 39 (28 ·3) 22 (20 ·8) 18 (17 ·3) 14 (21 ·2) 0 ·21 
Fever 119 (86 ·2) 79 (74 ·5) 68 (65 ·4) 39 (59 ·1) < 0 ·001 
Weight loss 118 (85 ·5) 83 (78 ·3) 61 (58 ·7) 46 (69 ·7) < 0 ·001 
Night sweats 93 (67 ·4) 74 (69 ·8) 58 (55 ·8) 41 (62 ·1) 0 ·14 
No symptoms 2 (1 ·4) 2 (1 ·9) 6 (5 ·8) 3 (4 ·5) 0 ·20 
TB diagnosis 
Smear positive 103 (74 ·6) 57 (53 ·8) 30 (28 ·8) 55 (45 ·5) < 0 ·001 
Smear negative, x-ray positive 35 (25 ·4) 42 (39 ·6) 42 (40 ·4) 38 (31 ·4) 
X-ray positive, no smear examination 0 5 (4 ·7) 29 (27 ·9) 27 (22 ·3) 
Other ∗∗ 0 2 (1 ·9) 3 (2 ·9) 1 (0 ·8) 
Duration of cough prior to diagnosis, days, 
median (IQR) 
68 (36–125) 35 (16–66) 63 (34–122) 53 (32–95) < 0 ·001 
Duration of cough prior to presentation to formal 
HCP, days, median (IQR) 
31 (30–92) 30 (7–55) 15 (7–31) 30 (14–31) < 0 ·001 
Received antibiotics prior to TB diagnosis 99 (71 ·7) 73 (68 ·9) 65 (62 ·5) 43 (65 ·2) 0 ·71 
a USD = United States dollar (1 USD = 13,755 Indonesian Rupiah). 
b Comorbidities were self-reported by the patients. 
c More than one TB symptom may be indicated. 
∗ Cardiovacular disease includes hypertension, heart disease, dyslipidemia. 
∗∗ 3 (0 ·7%) patients were diagnosed using PCR-TB (Xpert) and 3 (0 ·7%) by IGRA test. CHC = Community Health Center, HCP = Healthcare provider, IQR = Interquartile range, 
TB = tuberculosis. 
( Fig. 2 ). For those recruited from CHCs, most had first visited infor- 
mal (46 ·3%) or private providers (32 ·4%), but diagnosis was usually 
(62 ·5%) made at CHCs ( Fig. 2 a). For those recruited from PPs, the 
site of initial presentation was similar, but almost all (98 ·4%) were 
diagnosed by PPs ( Fig. 2 b). For those recruited at public and pri- 
vate hospitals, initial presentation showed a similar pattern, but al- 
most all diagnoses (93–94%) were made at a hospital ( Figs. 2 c and 
2 d). With respect to treatment, those who were treated at public 
HCPs had been diagnosed at a variety of different types of HCPs, 
whereas for those who were treated in private care almost all had 
been diagnosed by private HCPs. Overall, only one in five patients 
received their TB diagnosis, and less than a quarter started their 
TB treatment, at healthcare facilities where they first presented 
( Fig. 2 e). 
Specifically, with respect to obtaining a diagnosis, patients gen- 
erally underwent a complex journey visiting both private and pub- 
lic providers. Fig. 3 displays the number and nature of the visits of 
TB patients before a diagnosis was made, stratified by recruitment 
site. The median number of visits until a TB diagnosis was made 
was six (Interquartile Range (IQR) 4–8), and for some patients that 
it took up to 20 visits before a diagnosis was made. Furthermore, 
only about 50% of cases were bacteriologically confirmed. A first 
visit to an informal provider before going to a formal (private or 
public) HCP was reported by 46 ·3%, 32 ·7%, 35 ·7% and 46 ·0% of par- 
ticipants recruited from CHC, public or private hospitals, and PPs, 
respectively. Patients recruited at the primary care level ( Figs. 3 a 
and 3 b) had slightly more visits compared to those recruited at 
the hospital level ( Figs. 3 c and 3 d). 
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Fig. 3. Proportion of patients diagnosed, or with a missed diagnosis, over sequential visits, stratified by site of recruitment ( N = 401). 13 patients were excluded because 
they didn’t have TB symptoms. Horizontal axis indicates sequence of visit and vertical axis shows the proportion of diagnosed or missed opportunity to be diagnosed as TB 
at that particular visit based on type of HCP. The black line indicates the cumulative proportion of patients diagnosed with TB. HCP = healthcare provider, TB = tuberculosis. 
= visited informal provider (L0), = missed opportunity to be diagnosed as TB at CHC (L1a), = missed opportunity to be diagnosed as TB at private practitioner 
(L1b), = missed opportunity to be diagnosed as TB at public hospital (L2a), = missed opportunity to be diagnosed as TB at private hospital (L2b), = diagnosed 
at CHC (L1a), = diagnosed at private practitioner (L1b), = diagnosed at public hospital (L2a), = diagnosed at private hospital (L2b). 
Table 3a 
Median delay in days to care-seeking, diagnosis and treatment according to site of recruitment ( N = 414). 
Delay type Site of recruitment 
Community Health Center n = 138 Public hospital n = 106 Private hospital n = 104 Private Practitioner n = 66 p-value 
Patient delay ( n = 401) ∗ 31 (30–68) 30 (10–55) 15 (7–31) 30 (14–31) < 0 ·001 
Diagnostic delay 28 (13–55) 30 (12–68) 19 (5–38) 15 (3–46) 0 ·05 
Treatment delay 1 (0–3) 0 (0–1) 1 (0–3) 0 (0–2) 0 ·001 
Health system delay 32 (15–60) 30 (14–68) 22 (9–39) 16 (7–46) 0 ·02 
Total delay ( n = 401) ∗ 80 (43–137) 69 (38–127) 45 (29–76) 56 (34–102) 0 ·001 
3.3. Delays to care seeking, diagnosis and initiation of treatment, and 
associated risk factors 
There were substantial patient and diagnostic delays, while 
time to treatment initiation after diagnosis was generally short. 
Of patients recruited from CHC, public hospital, private hospital, 
and PP, 63 ·2%; 41 ·3%; 32 ·7%; and 47 ·6%, respectively, experienced 
a delay of more than 30 days before visiting any HCP for their TB 
symptoms ( Table 3 ). Patient delay was associated with being male 
(aOR 1 ·6, 95% CI 1 ·0–2 ·7), having a lower level of education (aOR 
1 ·9, 95% CI 1 ·1–3 ·1), and not having health insurance (aOR 2 ·1, 95% 
CI 1 ·2–3 ·5; Table 4 ). The median time from the first presentation 
to any HCP to their TB diagnosis was 23 days (IQR 9–52); 75 ·6% 
(313/414) experienced delay of more than 7 days. Diagnostic delay 
was associated with not having insurance (aOR = 1 ·9, 95%CI 1 ·0–
3 ·6), multiple visits to HCPs (aOR = 12 ·4, 95%CI 6 ·3–24 ·6), and an 
initial visit to a PP (aOR = 2 ·6, 95%CI 1 ·3–5 ·2). When using a 30-day 
cut-off, being male (aOR 1 ·7, 95% CI 1 ·0–2 ·8), multiple visits to 
HCPs (aOR 9 ·4, 95% CI 5 ·5–16 ·1) and first visiting a PP (aOR 3 ·2, 
95% CI 1 ·8–5 ·6) were factors associated with diagnostic delay. 
After receiving a TB diagnosis, 278 (69 ·3%) patients were started 
on TB treatment within one day, while almost a quarter (21 ·9%) 
experienced treatment delay for more than two days. Having mul- 
tiple visits before TB diagnosis (aOR 2 ·2, 95% CI 1 ·2–3 ·9) and being 
diagnosed with TB by a PP (aOR 5 ·7, 95% CI 1 ·6–21 ·1) were asso- 
ciated with longer treatment delay. The median total time from 
first onset of TB symptoms to treatment initiation was 65 days 
(IQR 37–119). 
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Table 3b 
Median delay in days to care-seeking, diagnosis and treatment according to first health care provider encountered ( N = 414). 
Delay type Type of HCP first visited prior to presentation at site of recruitment 
Informal providers/ 
pharmacy/drug store n = 161 
Community Health 
Center n = 60 
Public hospital n = 9 Private hospital n = 36 Private Practitioner 
n = 148 
p-value 
Patient delay ( n = 401) ∗ 31 (15–61) 31 (14–31) 47 (30–110) 30 (7–61) 30 (14–61) 0 ·08 
Diagnostic delay 23 (10–45) 18 (7–47) 10 (1–22) 7 (0–22) 31 (14–65) < 0 ·001 
Treatment delay 1 (0–2) 1 (0–2) 1 (0–4) 1 (0–3) 1 (0–2) 0 ·15 
Health system delay 28 (12–47) 19 (10–53) 11 (2–27) 10 (2–29) 34 (14–68) < 0 ·001 
Total delay ( n = 401) ∗ 63 (41–107) 57 (34–132) 72 (46–111) 37 (18–104) 71 (37–123) 0 ·31 
∗ 13 people did not present with symptoms and were therefore excluded from this delay calculation. Time delay is presented as a median and IQR (interquartile range). 
HCP = Healthcare provider. 
Table 4 
Factors associated with patient, diagnostic and treatment delay ( N = 414). 
Patient delay ∗∗ ( > 30 days) Diagnostic delay ( > 7 days) Treatment delay ( > 2 days) 
Characteristic Crude OR (CI) p value Adjusted OR ∗
(CI) 
p value Crude OR (CI) p value Adjusted OR ∗
(CI) 
p value Crude OR (CI) p value Adjusted OR ∗
(CI) 
p value 
Age, median (IQR) 1 ·0 (0 ·9–1 ·0) 0 ·5 1 ·0 (0 ·9–1 ·0) 0 ·6 1 ·0 (0 ·9–1 ·0) 0 ·5 0 ·9 (0 ·9–1 ·0) 0 ·3 1 ·0 (0 ·9–1 ·0) 0 ·1 1 ·0 (0 ·9–1 ·0) 0 ·9 
Sex 
Male 1 ·2 (0 ·8–1 ·8) 0 ·4 1 ·6 (1 ·0–2 ·7) 0 ·05 1 ·3 (0 ·8–2 ·1) 0 ·3 0 ·7 (0 ·5–1 ·8) 0 ·9 0 ·7 (0 ·5–1 ·2) 0 ·2 0 ·9 (0 ·5–1 ·5) 0 ·7 
Female Reference Reference Reference Reference Reference Reference 
Education 
Up to secondary 
school 
1 ·8 (1 ·2–2 ·6) 0 ·01 1 ·9 (1 ·1–3 ·1) 0 ·02 0 ·8 (0 ·5–1 ·3) 0 ·4 0 ·6 (0 ·4–1 ·1) 0 ·1 1 ·6 (1 ·0–2 ·6) 0 ·04 1 ·6 (0 ·9–2 ·9) 0 ·1 
High school or 
greater 
Reference Reference Reference Reference Reference Reference 
Employment 
Unemployed 1 ·1 (0 ·8–1 ·7) 0 ·6 1 ·4 (0 ·8–2 ·3) 0 ·3 0 ·7 (0 ·5–1 ·2) 0 ·2 0 ·7 (0 ·4–1 ·2) 0 ·2 0 ·9 (0 ·6–1 ·5) 0 ·8 0 ·9 (0 ·5–1 ·5) 0 ·6 
Employed Reference Reference Reference Reference Reference Reference 
Average household income/month, USD 
0–230 1 ·3 (0 ·83–1 ·90) 0 ·3 0 ·9 (0 ·6–1 ·4) 0 ·6 0 ·9 (0 ·4–2 ·1) 0 ·9 1 ·2 (0 ·4–3 ·1) 0 ·8 1 ·4 (0 ·9–2 ·3) 0 ·2 1 ·2 (0 ·7–2 ·0) 0 ·6 
≥231 Reference Reference Reference Reference Reference Reference 
Insurance 
Yes Reference Reference Reference Reference 
No 2 ·4 (1 ·5–3 ·7) < 0 ·01 2 ·1 (1 ·2–3 ·5) 0 ·01 1 ·2 (0 ·8–1 ·9) 0 ·4 1 ·9 (1 ·0–3 ·6) 0 ·04 0 ·9 (0 ·5–1 ·5) 0 ·6 0 ·8 (0 ·4–1 ·4) 0 ·4 
Comorbidities (HIV/DM/Hypertension) 
Yes 0 ·9 (0 ·5–1 ·5) 0 ·6 1 ·5 (0 ·8–3 ·2) 0 ·3 1 ·3 (0 ·7–2 ·4) 0 ·5 1 ·4 (0 ·7–3 ·0) 0 ·4 1 ·3 (0 ·7–2 ·5) 0 ·4 1 ·0 (0 ·5–2 ·3) 0 ·9 
No Reference Reference Reference Reference Reference Reference 
Level of TB knowledge 
Poor 1 ·0 (0 ·7–1 ·5) 0 ·9 0 ·9 (0 ·5–1 ·7) 0 ·7 0 ·9 (0 ·6–1 ·5) 0 ·9 1 ·4 (0 ·8–2 ·5) 0 ·2 1 ·1 (0 ·7–1 ·7) 0 ·7 1 ·0 (0 ·6–1 ·7) 0 ·9 
Good Reference Reference Reference Reference Reference Reference 
Number of visits to HCP before diagnosis 
< 6 visits Reference Reference Reference Reference 
≥6 visits 10 ·9 (6 ·0–19 ·8) < 0 ·001 12 ·4 
(6 ·3–24 ·6) 
< 0 ·001 1 ·9 (1 ·2–2 ·9) 0 ·01 2 ·2 (1 ·2–3 ·9) 0 ·01 
Type of HCP visited at initial presentation prior to TB diagnosis 
Informal provider Reference Reference Reference Reference 
Private practitioner 1 ·2 (0 ·7–2 ·1) 0 ·6 2 ·6 (1 ·3–5 ·2) 0 ·01 0 ·9 (0 ·5–1 ·5) 0 ·7 0 ·7 (0 ·4–1 ·4) 0 ·3 
CHC 0 ·6 (0 ·3–1 ·2) 0 ·2 1 ·2 (0 ·6–2 ·7) 0 ·6 0 ·9 (0 ·5–1 ·9) 0 ·9 0 ·6 (0 ·3–1 ·4) 0 ·2 
Public or private 
hospital 
0 ·2 (0 ·1–0 ·4) < 0 ·001 0 ·6 (0 ·3–1 ·4) 0 ·2 1 ·9 (0 ·9–3 ·9) 0 ·07 1 ·9 (0 ·8–4 ·6) 0 ·2 
Site of TB diagnosis 
CHC Reference Reference 
Private practitioner 1 ·0 (0 ·5–2 ·1) 0 ·9 5 ·7 (1 ·6–21 ·1) 0 ·01 
Public hospital 0 ·7 (0 ·4–1 ·4) 0 ·3 1 ·3 (0 ·5–3 ·2) 0 ·6 
Private hospital 1 ·3 (0 ·7–2 ·4) 0 ·7 0 ·8 (0 ·2–4 ·1) 0 ·8 
∗ Adjusted for site of recruitment. 
∗∗ 13 people did not present with symptoms and were therefore excluded from this delay calculation. CHC = Community Health Center, HCP = Healthcare provider, OR = Odds 
ratio, CI = Confidence interval, TB = tuberculosis, USD = United States dollar. 
4. Discussion 
In this study, patient pathways to TB care were complex and 
characterized by multiple visits to HCPs. The majority of TB pa- 
tients first sought care from informal providers and PPs, who 
mostly lack TB diagnostic capacity. Only a small proportion of TB 
patients were diagnosed where they first presented and many en- 
countered significant diagnostic and treatment delays, with an av- 
erage total delay of two months. Patient delays were longer for 
those who had no health insurance or a lower education level, and 
diagnostic and treatment delays were longer for those who first 
went to PPs. The complexities of patient health seeking and the 
mix of private and public providers in this setting present signifant 
challenges for the provision of efficient TB diagnosis and treatment. 
In Indonesia, approximately 74% of all HCPs at the primary care 
level are working outside the public system [13] . Informal HCPs 
and the private sector are therefore key entry points for patients 
seeking health care, even though TB diagnosis and treatment ser- 
vices are mainly available (and free-of-charge) in the public health 
system. Early on, patients may have non-specific symptoms, and 
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prefer to visit informal and private providers [21] , often for rea- 
sons of convenience [22] Our findings are consistent with previous 
studies in other high TB-burden settings such as in India [ 23 , 24 ], 
China [25] , Uganda [26] , and Tanzania [27] , which were also found 
to have complex pathways generating diagnostic delays. 
That few patients were successfully diagnosed at their initial 
visit, indicates a big gap between patient preference and diagnostic 
capacity of the HCP where they first present. Less than a quarter 
of HCPs where presumptive TB cases first present have sputum mi- 
croscopy available and none use molecular testing or culture. Even 
for those patients that access a public provider early, repeated vis- 
its are common before referral for sputum smear examination oc- 
curs. Our analyses show that most patients with typical TB symp- 
toms first visited primary level HCPs, but TB diagnosis was mostly 
established at secondary level healthcare indicating lack of confi- 
dence or familiarity in diagnosing TB among clinicians at the pri- 
mary level [5] . A systematic review from India [28] showed that 
only half of HCPs knew that people with unexplained cough should 
be evaluated for TB. Moreover, prescribing antibiotics before order- 
ing a sputum test is common among PPs and associated with diag- 
nostic delay. Antibiotic use was more common among TB patients 
who first presented to informal providers and PPs. This practice 
of using medication as a diagnostic tool is worrisome [29] . Beside 
low awareness of unexplained cough as a key symptom of pul- 
monary TB among PPs, insensitive diagnostic tools such as smear 
microscopy also lead to delayed diagnosis [30] . 
Almost half of the patients in this study had at least a one- 
month delay in seeking care for their symptoms and only 50% 
had good knowledge about TB. Consistent with other studies we 
also found an association of lower education level with longer de- 
lay [10] , indicating a need for interventions to increase awareness 
and knowledge about TB in the general population. Our findings of 
longer delay among men is supported by some [ 31 , 32 ], but not all 
studies [ 11 , 12 ]. The association between health insurance owner- 
ship and earlier presentation and treatment is consistent with the 
findings of a recent study in Vietnam; having health insurance in- 
fluences patients’ behavior towards seeking care from a formal HCP 
[33] . Patients diagnosed by PPs reported longer delays. In Indone- 
sia, most anti-TB treatment resources are within the public sector, 
while only 36% of the formal private sector has TB treatment avail- 
able [22] . 
Our study is the first of its type in Indonesia, combining pa- 
tient pathway and time to TB diagnosis and treatment from both 
the public and private sectors at different levels of healthcare fa- 
cilities. Prior studies have been conducted only on patients treated 
under the public system [ 17 , 34 ]. Our study has several limitations. 
First, we relied on patients’ recall about their pathways. However, 
patients were asked to relate their experiences to specific events 
or dates to prompt their recall and where possible dates were 
checked against available medical records. Second, the recruitment 
numbers were not in proportion to the actual numbers of patients 
treated in the different recruitment facilities, although we made 
some attempt to estimate relative proportions. To take this into ac- 
count, site of recruitment was included as an adjusted variable in 
the logistic regression analysis. Third, this study was conducted in 
Bandung City, an urban setting in West Java, and therefore may not 
be representative of TB patients throughout Indonesia. 
A number of recommendations can be made from our study. 
First , partnerships between the public and private sectors should 
be strengthened. Interventions aiming to better engage the pri- 
vate sector with the TB program are worth exploring, including 
realigning patients’ preferences with allocation of diagnostic re- 
sources. Improving TB care and control requires a patient-centered 
approach and removal of crucial barriers for accessing care [35] . 
Second , universal health insurance coverage would likely improve 
timely TB diagnosis and treatment. Health insurance can facilitate 
more direct patient journeys to a TB diagnosis and improve treat- 
ment outcomes. Targeted interventions for social minorities to en- 
courage demand for TB services for example by providing social 
protection for TB patients could reduce patient delay [4] . Third , 
patient access to TB diagnostic tools needs to be optimised. For 
example, increasing provision of Xpert MTB/RIF as a point-of-care 
test at healthcare facilities, strengthening the referral system for 
PPs to prioritize presumptive cases, and establishing systems to 
transport specimens from both the public and private sector to a 
central laboratory [26] , may help streamline pathways to care. So 
far, roll out of Xpert MTB/RIF in Indonesia has been limited. Chest 
X-ray might also be mandated as a screening tool to prioritize pa- 
tients for further microbiological testing [36] . Only about 50% of 
patients were bacteriologically confirmed, and by all means, a sim- 
ple and sensitive point-of-care test, preferably using blood or urine 
rather than sputum, could dramatically transform patient pathways 
in Indonesia and similar TB-endemic settings. 
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